A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer

Lung Cancer

Volumn 69, Issue 1, 2010, Pages 99-104

  Kaira, Kyoichi ^a   Sunaga, Noriaki ^a   Tomizawa, Yoshio ^b   Yanagitani, Noriko ^a   Shimizu, Kimihiro ^a   Imai, Hisao ^a   Utsugi, Mitsuyoshi ^a   Iwasaki, Yasuki ^a   Iijima, Hironobu ^b   Tsurumaki, Hiroaki ^b   Yoshii, Akihiro ^b   Fueki, Naoto ^c   Hisada, Takeshi ^a   Ishizuka, Tamotsu ^a   Saito, Ryusei ^b   Mori, Masatomo ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION   (Japan)

^c Jobu Hospital for Respiratory Disease   (Japan)

Author keywords

Amrubicin; Non small cell lung cancer; Phase II trial; Previously treated lung cancer; Relapse; Small cell lung cancer

Indexed keywords

AMRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; ANTHRACYCLINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER RADIOTHERAPY; CANCER RELAPSE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; INFECTION; INTERSTITIAL PNEUMONIA; LEUKOPENIA; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; SMALL CELL LUNG CARCINOMA;

AGED; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SMALL CELL LUNG CARCINOMA;

EID: 77953357859     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.09.012     Document Type: Article

References (22)

1. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer statistics, 2005. CA Cancer J Clin 2005, 55:10-30.
2. Tani N., Yabuki M., Komuro S., Kanamaru H. Characterization of the enzymes involved in the vitro metabolism of amrubicin hydrochloride. Xenobiotica 2005, 35:1121-1133.
3. Yamaoka T., Hanada M., Ichii S., Morisada S., Noguchi T., Yanagi Y. Cytotoxic amrubicinol on human tumor cells. Jpn J Cancer Res 1998, 89:1067-1073.
4. Ogawa M. Novel anticancer drugs in Japan. J Cancer Res Clin Oncol 1999, 125:134-140.
5. Kurata T., Okamoto I., Tamura K., Fukuoka M. Amrubicin for non-small-cell lung cancer and small-cell lung cancer. Invest New Drugs 2007, 25:499-504.
6. Okamoto I., Hamada A., Matsunaga Y., Sasaki J., Fujii S., Uramoto H., et al. Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer. Cancer Chemother Pharmacol 2006, 57:282-288.
7. Onoda S., Matsuda N., Seto T., Eguchi K., Takiguchi Y., Isobe H., et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol 2006, 24:5448-5453.
8. Igawa S., Yamamoto N., Ueda S., Ono A., Nakamura Y., Tsuya A., et al. Evaluation of the recommended dose and efficacy of amrubicin as second- and third-line chemotherapy for small cell lung cancer. J Thorac Oncol 2007, 2:741-744.
9. Inoue A., Sugawara S., Yamazaki K., Maemondo M., Suzuki T., Gomi K., et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 2008, 26:5401-5406.
10. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216.
11. Takeda K., Takifuji N., Negoro S., Furuse K., Nakamura S., Takada Y., et al. Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small cell lung cancer: a West Japan Thoracic Oncology Group (WJTOG) Study. Invest New Drugs 2007, 25:377-383.
12. Sawa T., Yana T., Takada M., Sugiura T., Kudoh S., Kamei T., et al. Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small cell lung cancer (Study 1): a West Japan Thoracic oncology Group (WJTOG) trial. Invest New Drugs 2006, 24:151-158.
13. Igawa S., Takahashi T., Nakamura Y., Tsuya A., Ono A., Shukuya T., et al. Efficacy of amrubicin for non-small cell lung cancer after failure of two or more prior chemotherapy. Anticancer Res 2008, 26:3855-3858.
14. Fossella F.V., Lee J.S., Shin D.M., Calayag M., Huber M., Perez-Soler R., et al. Phase II study of docetaxel for advanced or metastatic platinum refractory non-small cell lung cancer. J Clin Oncol 1995, 13:654-751.
15. Arango B.A., Castrellon A.B., Santos E.S., Raez L.E. Second-line therapy for non-small-cell lung cancer. Clin Lung Cancer 2009, 10:91-98.
16. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18:2095-2103.
17. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597.
18. Maio M.D., Chiodini P., Georgoulias V., Hatzidaki D., Takeda K., Wachters F.M., et al. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2009, 27:1836-1843.
19. Ardizzoni A., Hansen H., Dombernowsky P., Gamucci T., Kaplan S., Postmus P., et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease-The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 1997, 15:2090-2096.
20. Eckardt J.R., Bentsion D.L., Lipatov O.N., Polyakov I.S., Mackintosh F.R., Karlin D.A., et al. Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer. J Clin Oncol 2009, 20:2046-2051.
21. Shimokawa T., Shibuya M., Kitamura K., Hosomi Y., Hibino S., Ota T., et al. Retrospective analysis of efficacy and safety of amrubicin in refractory and relapsed small-cell lung cancer. Int J Clin Oncol 2009, 14:63-69.
22. Ciuleanu T., Brodowicz T., Belani C., Kim J., Krzakowski M., Laack E., et al. Maintenance pemetrexed plus nest supportive care (BSC) versus placebo plus BSC: a phase III study [abstract]. J Clin Oncol 2008, 26:426s.